EVOLUS, INC. Depreciation
EVOLUS, INC. (EOLS) reported Depreciation of $461.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-05
- EVOLUS, INC. depreciation for the quarter ending 2026-06-30 was $461.00K, a 88.93% increase year-over-year.
- EVOLUS, INC. depreciation for the quarter ending 2026-03-31 was $453.00K, a 57.84% increase year-over-year.
- EVOLUS, INC. depreciation for the quarter ending 2025-12-31 was $431.00K, a 11.37% increase year-over-year.
- EVOLUS, INC. depreciation for the quarter ending 2025-09-30 was $271.00K, a 4.24% decline year-over-year.
- EVOLUS, INC. depreciation for fiscal 2025 was $1.23M, a 3.27% increase from fiscal 2024.
- EVOLUS, INC. depreciation for fiscal 2024 was $1.19M, a 19.28% increase from fiscal 2023.
- EVOLUS, INC. depreciation for fiscal 2023 was $1.00M, a 168.36% increase from fiscal 2022.
- EVOLUS, INC. depreciation for fiscal 2022 was $373.00K.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2026-06-30 | $461.00K 10-Q · filed 2026-08-05 | $914.00K 10-Q · filed 2026-08-05 | $1.34M derived: sum of 3 quarters · filed 2026-08-05 | $1.62M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $453.00K 10-Q · filed 2026-05-04 | $884.00K derived: sum of 2 quarters · filed 2026-05-04 | $1.16M derived: sum of 3 quarters · filed 2026-05-04 | $1.40M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $431.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $702.00K derived: sum of 2 quarters · filed 2026-03-03 | $946.00K derived: sum of 3 quarters · filed 2026-08-05 | $1.23M 10-K · filed 2026-03-03 |
| 2025-09-30 | $271.00K 10-Q · filed 2025-11-05 | $515.00K derived: sum of 2 quarters · filed 2026-08-05 | $802.00K 10-Q · filed 2025-11-05 | $1.19M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $244.00K 10-Q · filed 2026-08-05 | $531.00K 10-Q · filed 2026-08-05 | $918.00K derived: sum of 3 quarters · filed 2026-08-05 | $1.20M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $287.00K 10-Q · filed 2026-05-04 | $674.00K derived: sum of 2 quarters · filed 2026-05-04 | $957.00K derived: sum of 3 quarters · filed 2026-05-04 | $1.23M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $387.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $670.00K derived: sum of 2 quarters · filed 2026-03-03 | $939.00K derived: sum of 3 quarters · filed 2026-03-03 | $1.19M 10-K · filed 2026-03-03 |
| 2024-09-30 | $283.00K 10-Q · filed 2025-11-05 | $552.00K derived: sum of 2 quarters · filed 2025-11-05 | $807.00K 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $269.00K 10-Q · filed 2025-08-05 | $524.00K 10-Q · filed 2025-08-05 | ||
| 2024-03-31 | $255.00K 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | $1.00M 10-K · filed 2026-03-03 | |||
| 2022-12-31 | $373.00K 10-K · filed 2025-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |